(Erstwhile UTI Pharma & Healthcare Fund) The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. UTI Healthcare Fund is a Equity - Sectoral fund launched on 28 Jun 99. It is a fund with High risk and has given a Below is the key information for UTI Healthcare Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis UTI Healthcare Fund - G
Scheme Objective
CAGR
return of 14.9% since its launch. Ranked 40 in Sectoral
category. Return for 2024 was 42.9% , 2023 was 38.2% and 2022 was -12.3% . NAV as on 29 Aug 25 ₹288.514 ↓ -0.79 (-0.27 %) Net Assets (AUM) as on 31 Jul 2025 ₹1,146 Cr. Launch Date 28 Jun 1999 Category Equity - Sectoral Rating ☆ Type Open Ended Fund Risk High AMC UTI Asset Management Company Ltd Alpha Ratio 0.67 Expense Ratio 2.26 % Sharpe Ratio 0.433 Information Ratio -0.06 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹500 Exit Load 0-1 Years (1%),1 Years and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis
& more than 1 year are on CAGR (Compound Annual Growth Rate)
basis. as on 29 Aug 25 Duration Returns 1 Month -3.5% 3 Month 4% 6 Month 16.3% 1 Year 4.4% 3 Year 25.3% 5 Year 18.2% 10 Year 15 Year Since launch 14.9% Historical Annual Returns
Year Returns 2024 42.9% 2023 38.2% 2022 -12.3% 2021 19.1% 2020 67.4% 2019 1.2% 2018 -7.5% 2017 6.2% 2016 -9.7% Growth of 10k Over Years
Date Value 31 Jul 20 ₹10,000 31 Jul 21 ₹14,212 31 Jul 22 ₹12,434 31 Jul 23 ₹15,086 31 Jul 24 ₹22,089 31 Jul 25 ₹25,028 Asset Allocation
Asset Class Value Cash 1.1% Equity 98.9% Sector Allocation
Sector Value Health Care 97.97% Basic Materials 0.93% Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMADrug Manufacturers - Specialty & Generic 10% ₹111 Cr 661,016 Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | 500087Drug Manufacturers - Specialty & Generic 5% ₹60 Cr 400,000 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | 532331Drug Manufacturers - Specialty & Generic 5% ₹54 Cr 210,000
↑ 37,171 Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Dec 20 | PGHLDrug Manufacturers - Specialty & Generic 4% ₹47 Cr 80,283 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDYDrug Manufacturers - Specialty & Generic 4% ₹46 Cr 360,000
↓ -36,000 Glenmark Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Mar 24 | 532296Drug Manufacturers - Specialty & Generic 4% ₹44 Cr 250,000
↓ -25,250 Lupin Ltd (Healthcare)
Equity, Since 28 Feb 25 | 500257Drug Manufacturers - Specialty & Generic 4% ₹39 Cr 200,000
↑ 60,000 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSPMedical Care Facilities 3% ₹38 Cr 53,000
↓ -3,271 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLABDrug Manufacturers - Specialty & Generic 3% ₹38 Cr 56,000 Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Dec 20 | 532843Medical Care Facilities 3% ₹37 Cr 465,000
Talk to our investment specialistFund Managers
Name Since Tenure Kamal Gada 2 May 22 3.25 Yr. Custodians
Company Address Axis Bank Ltd null Deutsche Bank AG MUMBAI Deitsche bank,Kodak House Stock Holding Corporation of India Mittal Court, ‘B’ Wing,,Nariman Point Registrar & Transfer Agent
KFin Technologies Ltd Address 138 -Suyesh Solitaire, Nr. Podar International School,Kudasan, Gandhinagar, Gujarat FAX N.A Email N.A Administrator Companies
Company Address UTI Asset Management Co Ltd PMS Division, UTI - Tower, “Gn” Block, Bandra Kurla Complex, Mumbai- 400051 Auditors
Company Address S. R. BATLIBOI & Co Express Tower, 6th Floor,Nariman Point,Mumbai All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year UTI Healthcare Fund
Growth ₹288.514
↓ -0.79 16.25 % 4.41 % 25.31 % 18.17 % UTI Healthcare Fund
Normal Dividend, Payout ₹222.981
↓ -0.61 16.25 % 4.41 % 25.31 % 18.17 % UTI Healthcare Fund
Normal Dividend, Reinvestment ₹222.981
↓ -0.61 16.25 % 4.41 % 25.31 % 18.17 % Data as on 29 Aug 25